XERS
NASDAQXeris Biopharma Holdings Inc.
Price$7.21+0.20 (+2.78%)
01:30 PM07:45 PM
News · 26 weeks50+400%
2025-12-282026-06-21
Mix2790d
- SEC Filings11(41%)
- Insider10(37%)
- Other4(15%)
- Earnings2(7%)
Latest news
25 items- PRXeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®Patent expected to provide intellectual property protection for Keveyis through 2039 Reinforces Xeris' commitment to the primary periodic paralysis community and the patients who rely on Keveyis Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced that today the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance with respect to U.S. Patent Application No. 17/151,405, entitled "Compositions and Methods of Use." The allowed claims in this applic
- SECXeris Biopharma Holdings Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
- PRXeris Biopharma Announces Private Exchange of Convertible NotesEliminates approximately $23 million of debt, resulting in approximately $2 million in annual interest savings Principal to be paid in cash, remainder in common stock Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 8.00% Convertible Senior Notes due 2028 (the "Notes"). Pursuant to the exchange agreements, Xeris has agreed, subject to customary closing conditions, to retire approximately $23 million aggregate princi
- INSIDERDirector Kong Garheng was granted 24,193 shares, increasing direct ownership by 11% to 238,337 units (SEC Form 4)4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
- INSIDERDirector Persky Marla sold $91,433 worth of shares (15,500 units at $5.90) as part of a pre-agreed trading plan and was granted 24,193 shares, increasing direct ownership by 6% to 150,693 units (SEC Form 4)4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
- INSIDERDirector Halkuff Dawn sold $121,886 worth of shares (20,000 units at $6.09) as part of a pre-agreed trading plan and was granted 24,193 shares, increasing direct ownership by 4% to 119,193 units (SEC Form 4)4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
- INSIDERDirector Bormann-Kennedy Barbara-Jean Anne sold $97,507 worth of shares (16,000 units at $6.09) as part of a pre-agreed trading plan and was granted 24,193 shares, increasing direct ownership by 6% to 150,693 units (SEC Form 4)4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
- INSIDERDirector Johnson John sold $91,422 worth of shares (15,000 units at $6.09) as part of a pre-agreed trading plan and was granted 24,193 shares, increasing direct ownership by 1% to 707,276 units (SEC Form 4)4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
- INSIDERDirector Brady James Aloysius was granted 24,193 shares, increasing direct ownership by 27% to 113,359 units (SEC Form 4)4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
- SECXeris Biopharma Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
- SECSEC Form 144 filed by Xeris Biopharma Holdings Inc.144 - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
- SECSEC Form 144 filed by Xeris Biopharma Holdings Inc.144 - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
- SECSEC Form 144 filed by Xeris Biopharma Holdings Inc.144 - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
- SECSEC Form 144 filed by Xeris Biopharma Holdings Inc.144 - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
- INSIDEROfficer Hecht Beth sold $100,982 worth of shares (16,667 units at $6.06) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,176,506 units (SEC Form 4)4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
- SECSEC Form 10-Q filed by Xeris Biopharma Holdings Inc.10-Q - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
- SECXeris Biopharma Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
- PRXeris Biopharma Reports First Quarter 2026 Financial ResultsTotal product revenue increased 43% year-over-year to over $82 million Recorlev net revenue increased 95% year-over-year to $50 million Tightens full-year 2026 total revenue guidance to $380 million to $390 million Hosts conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2026. "We are thrilled with our outstanding start to 2026, delivering first quarter net product revenue growth of 43%, reflecting the succe
- INSIDEROfficer Hecht Beth sold $103,805 worth of shares (16,667 units at $6.23) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,193,173 units (SEC Form 4)4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
- SECSEC Form DEFA14A filed by Xeris Biopharma Holdings Inc.DEFA14A - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
- SECSEC Form DEF 14A filed by Xeris Biopharma Holdings Inc.DEF 14A - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
- PRXeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026Conference Call to be Held at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2026 financial results before the open of the U.S. financial markets on Thursday, May 7, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. Interested parties may pre-register for the call here or via the "Events" section of the Investor Relations website. It is recommended that
- SECXeris Biopharma Holdings Inc. filed SEC Form 8-K: Leadership Update8-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
- INSIDERSEC Form 4 filed by Hecht Beth4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
- PRXeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on April 1, 2026, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 304,975 shares of its common stock to 90 new employee(s) under Xeris' Inducement Equity Plan. Xeris' Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or
XERS FAQ
7 questionsWhat does Xeris Biopharma Holdings Inc. do?
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a potentially life-threatening condition in...Where does XERS stock trade?
Xeris Biopharma Holdings Inc. (XERS) is listed on NASDAQ.What sector and industry is XERS in?
Xeris Biopharma Holdings Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Xeris Biopharma Holdings Inc. go public?
Xeris Biopharma Holdings Inc. (XERS) completed its IPO in 2018.What are analysts saying about XERS?
Xeris Biopharma Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight with a $900.00 price target on 2025-12-09. Recent price targets range from $300.00 to $1000.00.What companies are similar to XERS?
Notable peers in the same industry include APLS (Apellis Pharmaceuticals Inc.), RETA (Reata Pharmaceuticals Inc.), SBBP (Strongbridge Biopharma plc). Compare XERS side-by-side with any of them on Quantisnow.How can I track XERS on Quantisnow?
Quantisnow aggregates Xeris Biopharma Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow XERS to receive live email and push alerts on every new disclosure.